ClinVar Miner

Submissions for variant NM_000546.6(TP53):c.1025G>A (p.Arg342Gln)

gnomAD frequency: 0.00001  dbSNP: rs375338359
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen TP53 Variant Curation Expert Panel, ClinGen RCV001723808 SCV001949925 likely benign Li-Fraumeni syndrome 1 2021-08-11 reviewed by expert panel curation Transactivation assays show [retained/supertransactivation] function according to Kato, et al. and there is no evidence of a dominant negative effect or loss of function according to Giacomelli, et al. Oligomerization studies show the ability to form tetramers according to Kamada et al and Rollenhagen et al. (BS3; PMID: 12826609, 30224644, 20978130, 9766574). This variant has a BayesDel score < 0.16 and Align GVGD (Zebrafish) is Class C0 (BP4). In summary, TP53 c.1025G>A (p.Arg342Gln) meets criteria to be classified as likely benign for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: BS3, BP4.
Ambry Genetics RCV000213668 SCV000277448 likely benign Hereditary cancer-predisposing syndrome 2020-12-31 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
GeneDx RCV000478259 SCV000565624 likely benign not provided 2021-03-31 criteria provided, single submitter clinical testing Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Observed in individuals with breast and/or ovarian cancer in published literature (Castera 2014); Published functional studies demonstrate no damaging effect: oligomerization, transcription activity, and DNA binding activity similar to wild type (Rollenhagen 1998, Kato 2003, Imagawa 2009); This variant is associated with the following publications: (PMID: 10499619, 28993836, 14559903, 24549055, 9766574, 20978130, 19454241, 24665023, 28861920, 30840781, 25226867, 12826609, 30224644)
Invitae RCV000688863 SCV000816490 uncertain significance Li-Fraumeni syndrome 2023-08-21 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant disrupts the p.Arg342 amino acid residue in TP53. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 9766574, 10064694, 16007150, 19454241, 19806023, 20978130, 25226867, 25981898). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 342 of the TP53 protein (p.Arg342Gln). This variant is present in population databases (rs375338359, gnomAD 0.01%). This missense change has been observed in individual(s) with a personal and/or family history of breast and/or ovarian cancer (PMID: 24549055). ClinVar contains an entry for this variant (Variation ID: 233136). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 12826609, 29979965, 30224644) indicates that this missense variant is not expected to disrupt TP53 function. Experimental studies have shown that this missense change does not substantially affect TP53 function (PMID: 9766574, 12826609).
Color Diagnostics, LLC DBA Color Health RCV000213668 SCV002052756 uncertain significance Hereditary cancer-predisposing syndrome 2021-09-24 criteria provided, single submitter clinical testing This missense variant replaces arginine with glutamine at codon 342 of the TP53 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Experimental functional studies have shown this variant demonstrates DNA binding, tetramerization, transcriptional activation, and growth suppression activities similar to that of wild-type TP53 (PMID: 9766574, 12826609, 19454241, 20978130, 30224644). Another variant at the same amino acid position (p.Arg342Pro) has been shown to be deficient in these activities, indicating the amino acid position may be important for TP53 function. This variant has been reported in an individual affected with breast cancer in the literature (PMID: 24549055). This variant has been identified in 2/250992 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Mendelics RCV002247662 SCV002516104 benign not specified 2023-08-22 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV002247662 SCV002570646 likely benign not specified 2022-07-05 criteria provided, single submitter clinical testing Variant summary: TP53 c.1025G>A (p.Arg342Gln) results in a conservative amino acid change located in the p53, tetramerisation domain (IPR010991) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 250992 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1025G>A has been reported in the literature as a VUS in settings of multigene panel testing for hereditary breast and ovarian cancer (example, Castera_2014) and as a somatic variant in a variety of tumor settings (COSMIC database, Ten Broeke_2018). These report(s) do not provide unequivocal conclusions about association of the variant with Li-Fraumeni Syndrome. At-least one co-occurrence with another inferred germline pathogenic variant(s) has been reported in an individual with colorectal cancer and a characteristic MSH2-negative/MSH6-negative IHC pattern (Ten Broeke_2018, MSH2 c.1413del, p.Lys471fs), providing supporting evidence for a benign role. Multiple publications report experimental evidence evaluating an impact on protein function (example, Rollenhagen_1998, Kato_2003). These results showed no damaging effect of this variant based on overall transcription activity (TA) on eight different promoters as measured in yeast assays. Multiple clinical diagnostic laboratories and an expert panel (ClinGen TP53 Variant Curation Expert Panel) have submitted clinical-significance assessments for this variant to ClinVar after 2014 reporting the variant with conflicting assessments (likely benign, n=2; VUS, n=4). Some submitters cite overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as likely benign.
All of Us Research Program, National Institutes of Health RCV000688863 SCV004823725 uncertain significance Li-Fraumeni syndrome 2023-11-30 criteria provided, single submitter clinical testing This missense variant replaces arginine with glutamine at codon 342 of the TP53 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). Experimental functional studies have shown this variant demonstrates DNA binding, tetramerization, transcriptional activation, and growth suppression activities similar to that of wild-type TP53 (PMID: 9766574, 12826609, 19454241, 20978130, 30224644). Another variant at the same amino acid position (p.Arg342Pro) has been shown to be deficient in these activities, indicating the amino acid position may be important for TP53 function. This variant has been reported in an individual affected with breast cancer in the literature (PMID: 24549055). This variant has been identified in 2/250992 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.